DetermaIO Publications and Abstracts

Publications

Nielsen TJ, Ring BZ, Seitz RS, Hout DR, Schweitzer BL. (2021) A novel immuno-oncology algorithm measuring tumor microenvironment to predict response to immunotherapies. Heliyon Open 3:e06438 – View Article

Posters & Abstracts

Bianchini G, Dugo M, Huang C, Egle D, Bermejo B, Seitz RS, Nielsen TJJ. (2021) LBA12 – Predictive value of gene-expression profiles (GEPs) and their dynamics during therapy in the NeoTRIPaPDL1 trial. Abstract presented at the European Society for Medical Oncology Meeting.  – View Abstract


Seitz RS, Nielsen TJ, Schweitzer BL, Gandara DR, Parikh M, Ross DT. (2021) Association with immune checkpoint inhibitor efficacy of a 27-gene classifier in renal cell cancer.  Poster presented at the American Society of Clinical Oncology Annual Meeting.  – View Abstract

View Poster

View Video of Explanation


Seitz RS, Ross DT, Nielsen TJ, Hout DR, Schweitzer BL. (2021) Validation of a 27-gene immuno-oncology algorithm in metastatic urothelial carcinoma treated with an immune checkpoint inhibitor.  Presented at the American Association for Cancer Research Annual Meeting.  – View Abstract

View Video of Presentation


Seitz RS, Nielsen TJ, Schweitzer BL, Hout DR, Ross DT. (2021) Pathway modeling to translate the 27-gene immuno-oncology algorithm into bladder cancer.  Poster presented at the American Association for Cancer Research Annual Meeting. – View Abstract

View Poster

View Video of Explanation


Nielsen, TJ, McMahon FB, Spille J, Hout DR, Dickenson K, et al. (2020)  Tissue Requirements of a Novel 27-Gene Immuno-Oncology Algorithm Measuring Tumor Microenvironment to Predict Response to Immunotherapies.  Poster Presented at the Association for Molecular Pathology Annual Meeting & Expo


Nielsen T, Seitz R, Ross D, Hout D, Schweitzer B. (2020, November) Mesenchymal features of a novel 27-gene algorithm associate with canonical tumor promoting signaling pathways which may identify therapeutic options for immunotherapy resistant patients. Poster presented at Society for Immunotherapy of Cancer (SITC) Annual Meeting. – View Abstract


Iwase T, Pusztai L, Blenman K, Li X, Seitz R, et al. (2020, May). Validation of an immunomodulatory gene signature algorithm to predict response to neoadjuvant immunochemotherapy in patients with primary triple-negative breast cancer. Journal of Clinical Oncology. 38 supplement: abstr 3117. – View Abstract

View Poster


Ranganath H, Jain A, Smith J, Ryder J, Chaudry A, et al. (2019). One-year progression-free survival in lung cancer patients treated with immune checkpoint inhibitors is significantly associated with a novel immunomodulatory signature but not PD-L1 staining. Poster presented at Society for Immunotherapy of Cancer (SITC) Annual Meeting, National Harbor, MD. – View Abstract